Application Of Biotechnology On Malaria Transmission Blocking Vaccines In Iran | 4900
ISSN: 2155-952X

Journal of Biotechnology & Biomaterials
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Application of biotechnology on malaria transmission blocking vaccines in Iran

3rd World Congress on Biotechnology

Saber Gholizadeh

AcceptedAbstracts: J Biotechnol Biomater

DOI: 10.4172/2155-952X.S1.021

A malaria transmission Blocking Vaccine (TBV), Altruistic Vaccines, would work in combination with drugs and insecticides by blocking the transmission of the Plasmodium parasite from human to human. These vaccines are targeting the parasite?s sexual stages in the mosquito body. A large reduction in the burden of malaria has recently been achieved in Iran following the scaling up of effective treatment and vector control programmes. These achievements need for a partially effective malaria vaccine targeted at disease elimination. The problem is that most of Plasmodium parasites are not continues cultivable in laboratory especially to study sexual stages. Therefore biotechnology helps researchers to obtain sexual stages proteins for evaluation their role in transmission. Different type of epitopes from several parts of the life cycle of Iranian malaria parasites and their Anopheles vectors are already characterized and also have been challenged or in challenging process which contain immunogens from the disease life cycle. This presentation will discuss different malaria vaccine candidate genes studies from Iran with the focus on PvWARP, Plasmodium vivax Transmission Blocking Vaccine candidate gene. The details will be discussed in presentation time.
Saber Gholizadeh, Medical Entomologist (Biotechnology), graduated from Medical Entomology Department, Tehran University of Medical Sciences in 2010. He worked on Transmission Blocking Vaccine in Malaria. He was research staff and Co-PhD student in Pasteur Institute of Iran (PII), Biotechnology Research Center (BRC), Malaria and Vector Research Group (MVRG) since 2000. He is Assistant Prof. in Urmia University of Medical Sciences now. He has published more than 10 papers in reputed journals and serving as an editorial board member of Journal of Bacteriology and Parasitology.